Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Ardelyx Inc

ARDX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: STRONG BUY

Last Close

$4.06

▲ +3.84%

Market Cap $1.01B · Vol 774.76K

Key Metrics

P/E Ratio

N/A

FWD: 41.32

Market Cap

$1.01B

Small Cap

Div Yield

N/A

EPS Growth

+32.46%

YoY

RSI (14)

18.94

Momentum

Beta

0.67

vs Market

52W High

$8.40

51.67% below

52W Low

$3.87

5.05% above

Volume

774.76K

Avg 1.17M

P/B

8.53

Price-to-book

ROE

-36.21%

Return on equity

Free Float

95.73%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Ardelyx Inc (ARDX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ARDX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.50%

-21.32%

-37.15%

-40.90%

YTD

-30.36%

-30.48%

+5.45%

+181.94%

Financials & Valuation

TTM · Annual

Total Revenue	$407.32M
Net Income	$-61,599,000.00
Revenue Growth (YoY)	+23.77%
Gross Margin	90.29%
Operating Margin	-10.06%
Net Profit Margin	-15.12%
ROE	-36.21%
ROA · ROIC	-12.94% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	41.32
PEG Ratio	N/A
P/S	3.45
P/B	8.53
P/FCF	N/A
EPS Growth	+32.46%
Outstanding Shares	249.19M

Technical Indicators

50-Day SMA	$5.21
200-Day SMA	$5.99
RSI (14)	18.94
Beta	0.67
52-Week High	$8.40
52-Week Low	$3.87

Volume Today	774.76K
Avg Daily Volume (30D)	1.17M
Relative Volume	0.66x
Volatility (10D)	96.54
Volatility (30D)	60.67
Free Float	95.73%

Analyst Consensus

STRONG BUY

Current Price $4.06

Mean Target $13.06

52W Low$3.87 52W High$8.40

Current

Target

$3.87 $8.40

Current Analyst target

+221.76% upside potential · 12 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001WH4F33

ISINUS0396971071

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateOct 28, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical need. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. NHE3 is an antiporter expressed on the apical surface of the small and large intestines. Tenapanor is a minimally absorbed, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation. Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. In addition to commercializing IBSRELA and XPHOZAH, it is also developing a next-generation NHE3 inhibitor.